Business Standard

Resolved all issues leading to USFDA import alert on Vizag unit: Divis Labs

6 observations were made after the USFDA completed its audit on Sept 19

Pharmaceuticals, drugs, pharma industry, medical, health, lab
Premium

Illustration: Binay Sinha

BS Reporter Hyderabad
The Hyderabad-based Divis Laboratories Limited on Wednesday said that its Unit-2 plant in Visakhapatnam, which has been under import alert for the past six months, has resolved all issues related to the observations made by the US Food and Drug Administration (USFDA) in its latest CGMP audit. 

The successful implementation of the post-audit corrective plan is expected to pave the way for the lifting of the import alert, which was issued as the US drug regulator pointed some manufacturing-related issues in the said plant.

Responding to the news, the company scrip rose by 8.13 per cent to Rs 934 during

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in